Clinical trials: Preeclampsia Second Trimester

Preeclampsia, Severe Preeclampsia

Complement Regulation to Undo Systemic Harm in Preeclampsia

• Terminated
• Age: 13 years and older
• Phase 2
• Injection or infusion
• Results posted

This is a Phase II, single arm, open-label study to determine if treatment with eculizumab prolongs pregnancy compared to historical controls in women with preeclampsia between 23-30 weeks gestation.

Conditions

Preeclampsia, Severe Preeclampsia, Eculizumab, HELLP

Trial name

CRUSH (NCT04725812)

Testing

Eculizumab

Where

United States

Volunteers

2 people

Sponsor

Cedars-Sinai Medical Center